Genmab Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Genmab Bundle
See the Bigger Picture
Discover the strategic positioning of Genmab's product portfolio with our comprehensive BCG Matrix analysis. Understand which products are market leaders (Stars), which generate consistent revenue (Cash Cows), which are underperforming (Dogs), and which hold future potential (Question Marks). This preview offers a glimpse into Genmab's dynamic market presence.
To truly unlock Genmab's strategic roadmap and make informed decisions, you need the full picture. Purchase the complete BCG Matrix report to gain detailed quadrant placements, data-backed insights, and actionable recommendations for optimizing your investments and product strategy. Don't miss out on the clarity that a full analysis provides.
Stars
Epkinly (epcoritamab)
Epkinly, a significant product for Genmab, is positioned as a Star in the BCG Matrix due to its robust growth trajectory. Co-developed with AbbVie, Epkinly achieved $90 million in global net product sales in Q1 2025, marking a substantial 73% increase year-over-year.
The drug's market expansion is further fueled by recent approvals for follicular lymphoma in Japan and the EU. These approvals tap into the expanding hematologic malignancy market, reinforcing Epkinly's status as a high-growth asset for Genmab.
Genmab's strategic focus on enhancing commercialization efforts worldwide underscores its commitment to maximizing Epkinly's potential, aiming to establish it as a future blockbuster product. This investment is crucial for capturing a larger market share and solidifying its Star status.
Tecvayli (teclistamab)
Tecvayli (teclistamab) is a promising bispecific antibody targeting relapsed or refractory multiple myeloma, positioning it as a high-growth asset for Genmab. Its innovative T-cell engaging mechanism offers a distinct advantage in a competitive yet growing market for multiple myeloma therapies.
While precise 2024 sales data for Tecvayli alone isn't publicly itemized in the same way as some other Genmab products, it is recognized as a key contributor to the company's royalty revenue streams projected for both 2024 and 2025. This highlights its increasing market penetration and strategic importance within Genmab's portfolio.
Rinatabart Sesutecan (Rina-S)
Rinatabart Sesutecan, or Rina-S, is a key asset for Genmab, acquired in early 2024 through the acquisition of ProfoundBio Inc. This antibody-drug conjugate targets ovarian cancer, addressing a critical area with substantial unmet medical need.
Data presented in 2025 showcased Rina-S's promising antitumor activity in patients with advanced ovarian cancer, positioning it as a potentially differentiated therapeutic option. Genmab's strategic focus on advancing this late-stage program into a new Phase 3 trial underscores strong growth expectations and anticipated investment in its development.
Acasunlimab (GEN1046)
Acasunlimab (GEN1046), a bispecific antibody co-developed with BioNTech, targets both PD-L1 and 4-1BB. This dual action is designed to enhance the immune system's response against solid tumors, with a particular focus on non-small cell lung cancer (NSCLC). Genmab has taken over full development, indicating a significant belief in its future success.
The strategic decision by Genmab to solely pursue Acasunlimab's development highlights its potential as a key asset. The company's commitment is further underscored by the anticipation of Phase 2 data updates in 2025. These results will be crucial in defining Acasunlimab's trajectory within the highly competitive oncology market.
- Dual Mechanism: Targets PD-L1 and 4-1BB for enhanced anti-tumor immunity.
- Key Indication: Focus on solid tumors, including non-small cell lung cancer (NSCLC).
- Development Status: Genmab assumes sole responsibility, signaling strong confidence.
- Future Outlook: Phase 2 data update expected in 2025, poised to impact market potential.
DuoBody-CD40x4-1BB (GEN1042/BNT312)
DuoBody-CD40x4-1BB (GEN1042/BNT312) is a promising bispecific antibody developed in collaboration with BioNTech. It's currently in clinical trials for treating first-line head and neck squamous cell carcinoma (HNSCC), a significant area with a clear need for better treatment options.
The drug's dual targeting mechanism and encouraging early clinical results point to substantial growth potential. The market for HNSCC therapies is substantial, and improved first-line treatments are highly sought after, suggesting DuoBody-CD40x4-1BB could capture a notable market share.
- Target Indication: First-line head and neck squamous cell carcinoma (HNSCC).
- Development Status: Clinical development, with a decision on next steps anticipated in 2025.
- Market Potential: High growth potential in a market with significant unmet needs for improved first-line therapies.
- Strategic Importance: Represents a key asset in the Genmab-BioNTech collaboration, with potential to accelerate market entry and increase future market share.
Genmab's Stellar Growth: A Portfolio of Blockbusters
Epkinly is a prime example of a Star within Genmab's portfolio, demonstrating impressive growth. Its global net product sales reached $90 million in Q1 2025, a remarkable 73% increase year-over-year. Recent approvals in Japan and the EU for follicular lymphoma further bolster its position in the expanding hematologic malignancy market, solidifying its high-growth trajectory.
Tecvayli, targeting relapsed or refractory multiple myeloma, is another key growth driver for Genmab. While specific 2024 sales figures are not itemized, it's a significant contributor to royalty revenues, indicating increasing market penetration and strategic value. Its innovative T-cell engaging mechanism provides a competitive edge in the growing multiple myeloma treatment landscape.
Rinatabart Sesutecan (Rina-S), acquired in early 2024, targets ovarian cancer, a critical area with substantial unmet needs. Promising antitumor activity data presented in 2025 positions Rina-S as a differentiated therapeutic option, with Genmab advancing it into a Phase 3 trial, anticipating strong future growth.
Acasunlimab (GEN1046), a bispecific antibody co-developed with BioNTech, targets both PD-L1 and 4-1BB to enhance immune responses against solid tumors, particularly NSCLC. Genmab's assumption of sole development responsibility signals strong confidence, with Phase 2 data expected in 2025 to shape its market potential.
DuoBody-CD40x4-1BB (GEN1042/BNT312), a collaboration with BioNTech, is in clinical trials for first-line head and neck squamous cell carcinoma (HNSCC). Its dual targeting and early positive results suggest significant growth potential in a market seeking improved first-line therapies.
| Product | BCG Category | Key Indication | 2025 Q1 Sales/Status Update | Growth Indicator |
|---|---|---|---|---|
| Epkinly | Star | Follicular Lymphoma, Diffuse Large B-cell Lymphoma | $90 million net product sales (Q1 2025) | 73% YoY growth |
| Tecvayli | Star | Multiple Myeloma | Key contributor to royalty revenue streams | Increasing market penetration |
| Rinatabart Sesutecan (Rina-S) | Star | Ovarian Cancer | Advancing into Phase 3 trial | Strong growth expectations |
| Acasunlimab (GEN1046) | Star | Solid Tumors (NSCLC) | Phase 2 data update expected 2025 | Significant belief in future success |
| DuoBody-CD40x4-1BB (GEN1042/BNT312) | Star | Head and Neck Squamous Cell Carcinoma (HNSCC) | Decision on next steps anticipated 2025 | High growth potential |
What is included in the product
Detailed Word Document
The Genmab BCG Matrix provides a strategic overview of its product portfolio, categorizing each asset into Stars, Cash Cows, Question Marks, and Dogs.
This analysis guides investment decisions, highlighting which units Genmab should nurture, maintain, or divest to optimize its market position.
Customizable Excel Spreadsheet
A clear Genmab BCG Matrix visually clarifies strategic resource allocation, easing the pain of uncertain investment decisions.
Cash Cows
Darzalex (daratumumab)
Darzalex, a key product for Genmab, is a prime example of a cash cow within the BCG matrix. This drug, used to treat multiple myeloma, consistently generates significant royalty income for Genmab through its partnership with Johnson & Johnson.
In 2024, Darzalex achieved impressive worldwide net sales of $11,670 million. Projections for 2025 indicate even stronger performance, with estimated sales between $12.6 billion and $13.4 billion, which translates to approximately $2.2 billion in royalties for Genmab.
Darzalex's strong market position in multiple myeloma, further bolstered by its convenient subcutaneous formulation, ensures its status as a reliable and highly profitable revenue stream for Genmab.
Kesimpta (ofatumumab)
Kesimpta, developed with Novartis for multiple sclerosis, is a significant contributor to Genmab's royalty income. While not always spotlighted like Darzalex, its steady presence bolsters recurring revenue, suggesting a mature and reliable market position. This product diversifies Genmab's revenue beyond oncology, enhancing financial stability. In 2024, royalty revenues from Kesimpta are anticipated to remain a robust component of Genmab's diversified income streams.
Proprietary Technology Platforms (DuoBody, HexaBody)
Genmab's DuoBody and HexaBody platforms are cornerstones of its business, driving both internal drug development and external partnerships. These validated antibody technologies are key to creating next-generation therapeutics, positioning them as potential future Stars or Cash Cows themselves.
The ongoing licensing and co-development agreements for these platforms consistently bring in revenue via milestones and royalties. For instance, Genmab's collaboration with BioNTech on DuoBody technology for bispecific antibodies highlights the commercial success and ongoing value generation of these proprietary assets. These deals underscore the platforms' maturity and significant contribution to Genmab's financial health.
Established Collaborations
Genmab's established collaborations with industry leaders such as Johnson & Johnson, Novartis, and AbbVie are cornerstones of its Cash Cows. These long-term partnerships generate consistent and predictable revenue streams, primarily through royalties and collaboration fees. This stable income is crucial for funding ongoing research and development efforts.
These strategic alliances significantly de-risk the drug development and commercialization process for Genmab. By sharing the financial burden and leveraging the extensive commercial infrastructure of its partners, Genmab ensures a steady cash flow from its successful products. This model allows the company to focus on its core strengths in antibody development and innovation.
- Darzalex Royalties: Genmab receives substantial royalties from the sales of Darzalex (daratumumab), a blockbuster drug developed in partnership with Johnson & Johnson. In 2023, Darzalex sales reached approximately $11.4 billion globally, with Genmab benefiting significantly from this success.
- Reduced R&D Burden: Collaborations allow Genmab to access capital and expertise for late-stage clinical trials and global commercialization, reducing its own financial outlay and accelerating market penetration for its therapies.
- Diversified Revenue: Income from these partnerships provides a diversified and reliable revenue base, insulating the company from the inherent volatility of early-stage drug development.
- Partnership Stability: The established nature of these collaborations, often spanning many years, ensures continued revenue generation from approved and commercially successful products, solidifying their Cash Cow status.
Tivdak (tisotumab vedotin)
Tivdak, a treatment for recurrent or metastatic cervical cancer, is positioned as a Cash Cow for Genmab. Co-developed with Pfizer, it has secured full U.S. FDA approval and recent endorsements in Japan and the European Union. This signifies a strong market entry and potential for sustained revenue generation.
The drug's established efficacy and growing regulatory approvals are key drivers for Tivdak's role as a Cash Cow. Genmab anticipates significant and expanding net product sales and collaboration revenue stemming from Tivdak. This growth trajectory highlights its transition into a reliable income-generating asset within its specialized market segment.
Tivdak's robust performance is directly contributing to the overall increase in Genmab's net product sales and collaboration revenue. This financial impact underscores its growing importance as a stable, cash-generating product for the company.
- Tivdak's Market Position: Approved in the US, Japan, and EU for recurrent/metastatic cervical cancer.
- Revenue Potential: Expected to drive significant and growing net product sales and collaboration revenue for Genmab.
- Financial Contribution: Actively contributing to the growth of Genmab's overall revenue.
- Cash Cow Status: Transitioning into a stable, cash-generating asset in its niche market.
Genmab's Cash Cows: Driving Revenue Growth
Darzalex continues to be Genmab's flagship Cash Cow, demonstrating remarkable sales growth and generating substantial royalty income. Its strong market penetration in multiple myeloma, further enhanced by a convenient subcutaneous formulation, solidifies its position as a highly profitable and reliable revenue generator.
Kesimpta, while perhaps less prominent than Darzalex, also functions as a key Cash Cow by diversifying Genmab's revenue streams beyond oncology. Its steady contribution from the multiple sclerosis market enhances overall financial stability and provides recurring income.
Tivdak, approved for cervical cancer in major markets like the US, Japan, and the EU, is rapidly transitioning into a Cash Cow. Its growing market presence and anticipated significant sales growth are set to bolster Genmab's revenue and cash flow.
Genmab's underlying antibody technologies, DuoBody and HexaBody, act as foundational Cash Cows. Through licensing and co-development deals, these platforms consistently generate revenue via milestones and royalties, underpinning the company's ongoing innovation and financial health.
| Product/Platform | Therapeutic Area | Key Partner | 2024 Estimated Royalty/Revenue Contribution | Notes |
| Darzalex | Multiple Myeloma | Johnson & Johnson | ~$2.2 billion | Strong market position, subcutaneous formulation |
| Kesimpta | Multiple Sclerosis | Novartis | Significant, stable | Diversifies revenue, reliable market |
| Tivdak | Cervical Cancer | Pfizer | Growing | Expanding approvals, increasing sales |
| DuoBody/HexaBody Platforms | Various | Multiple partners (e.g., BioNTech) | Consistent milestones & royalties | Enables innovation and partnerships |
What You See Is What You Get
Genmab BCG Matrix
The Genmab BCG Matrix preview you're examining is the identical, fully formatted document you will receive immediately after purchase. This means no watermarks, no introductory sections, and no demo content—just the complete, analysis-ready strategic tool. You can confidently use this preview as a direct representation of the high-quality, actionable insights you'll gain. Once purchased, this comprehensive report will be instantly available for your strategic planning, empowering you to make informed decisions about Genmab's product portfolio.
Dogs
GEN1047 (CD3 and B7-H4 bispecific antibody)
GEN1047 (CD3 and B7-H4 bispecific antibody) has been classified as a 'Dog' within Genmab's BCG Matrix. This designation stems from Genmab's decision in November 2024 to terminate the early-stage clinical program for GEN1047. The company cited that the candidate did not meet its internal criteria for differentiated therapeutic potential.
This termination clearly signals a low market share and limited growth prospects for GEN1047. By divesting resources from this program, Genmab effectively acknowledged its low potential for future returns, treating it as a cash trap rather than a strategic investment.
GEN3017 (CD3xCD30 bispecific antibody)
GEN3017, a bispecific antibody targeting CD3xCD30, was a promising candidate for lymphoma treatment. However, Genmab decided to terminate its development in November 2024 as part of a strategic pipeline reprioritization. This decision was driven by an assessment of a low projected market share and the conclusion that continued investment would not provide adequate returns or a significant competitive edge.
The termination of GEN3017, similar to other pipeline adjustments, underscores Genmab's focus on maximizing resource allocation towards assets with higher commercial potential. The company’s commitment to a data-driven approach means that early-stage programs are continually evaluated against market dynamics and competitive landscapes, ensuring that capital is deployed where it can generate the greatest impact.
GEN1056 (undisclosed target, BioNTech collaboration)
GEN1056, a promising solid tumor drug candidate developed in partnership with BioNTech, was unfortunately terminated by Genmab in late 2024. This decision, even within a collaborative framework, underscores a lack of sufficient market potential or compelling clinical data to warrant further investment.
The discontinuation of GEN1056 points to a low projected market share and suggests the program did not align strategically with Genmab's long-term objectives. Consequently, this asset would be categorized as a 'Dog' within the BCG Matrix, reflecting its status as an underperforming or divested product.
Discontinued Preclinical Programs
Genmab actively manages its preclinical pipeline, a crucial aspect of its research and development strategy. Programs that don't meet stringent efficacy or differentiation benchmarks are often discontinued before advancing to clinical trials. This rigorous selection process ensures that resources are concentrated on the most promising therapeutic candidates.
These numerous early-stage terminations, while not individually publicized, represent a significant portion of R&D expenditure that doesn't translate into future revenue streams. Genmab's commitment to a 'high bar' for new therapies means that many innovative concepts are explored but ultimately not pursued if they don't demonstrate exceptional potential.
- Pipeline Filtration: Genmab's approach involves robust evaluation of preclinical assets to identify candidates with the highest probability of success.
- Resource Allocation: Discontinuing underperforming preclinical programs allows for more efficient allocation of R&D capital towards advanced and more promising projects.
- Strategic Focus: The company prioritizes the development of therapies that offer significant differentiation and address unmet medical needs, leading to the termination of less competitive early-stage concepts.
- R&D Efficiency: While exact figures for discontinued preclinical programs are not disclosed, this practice is a standard component of optimizing R&D investment and maximizing the return on innovation.
Products with Expired Patent Protection or Significant Biosimilar Competition
Products with expired patent protection or significant biosimilar competition would be classified as Dogs within Genmab's portfolio. These assets typically experience declining sales and limited future growth potential, contributing minimally to overall revenue or royalties. For instance, if Genmab had licensed an older antibody therapy whose patent expired in, say, 2023, and multiple biosimilar versions entered the market in 2024, its market share would likely shrink rapidly.
These products are characterized by their low market share and low growth prospects. Their contribution to Genmab's net revenue or royalty income would be negligible, potentially even negative if ongoing maintenance costs outweigh the revenue generated. For example, a product that once represented a significant revenue stream could see its sales plummet by over 50% within a year of biosimilar entry.
Genmab's strategic focus on investing in its robust late-stage pipeline and pursuing strategic acquisitions, such as the acquisition of Rina-S, indicates a clear intent to move away from these low-return assets. This proactive approach allows Genmab to reallocate resources towards higher-growth, innovative therapies, ensuring a more dynamic and profitable future portfolio.
- Low Market Share: Products facing biosimilar competition typically see their market share erode quickly.
- Declining Revenue: Expired patents often lead to price erosion and reduced profitability.
- Resource Reallocation: Genmab prioritizes investment in its innovative pipeline over legacy products.
- Strategic Divestment: The company actively seeks to divest or de-emphasize assets with limited growth potential.
Genmab's 2024 Pipeline: Strategic Cuts for Growth
Genmab's strategic pipeline management in 2024 led to the discontinuation of several early-stage candidates, including GEN1047, GEN3017, and GEN1056. These decisions, driven by a lack of differentiated therapeutic potential or insufficient market prospects, clearly place them in the 'Dog' category of the BCG Matrix. This classification signifies low market share and limited future growth, prompting Genmab to reallocate resources to more promising assets.
The termination of these programs reflects Genmab's rigorous R&D filtration process, ensuring capital is concentrated on therapies with higher commercial viability. By cutting losses on underperforming early-stage projects, Genmab aims to optimize its R&D efficiency and strengthen its overall portfolio for future growth and profitability.
Question Marks
GEN3014 (HexaBody-CD38)
GEN3014, also known as HexaBody-CD38, is positioned as a potential future blockbuster for Genmab, aiming to build upon the success of Darzalex. As an anti-CD38 monoclonal antibody, it's currently in clinical development, meaning its market share is negligible, placing it squarely in the question mark category of the BCG matrix.
The significant growth potential hinges on Johnson & Johnson's decision to exercise their licensing option, which is anticipated in the first quarter of 2025. If J&J moves forward and GEN3014 demonstrates superiority or a complementary role to Darzalex in treating multiple myeloma, it could capture a substantial market share, justifying its question mark status with high future growth prospects.
Rinatabart Sesutecan (Rina-S) in other indications
Rinatabart Sesutecan (Rina-S), while a promising Star in ovarian cancer, is positioned as a Question Mark for other indications. Its exploration in endometrial cancer, currently in a Phase 3 enrollment stage, exemplifies this.
These emerging applications are in nascent market stages, with significant investment poured into clinical trials and regulatory pathways. Success in these areas, particularly the ongoing Phase 3 trial for endometrial cancer, could transform these Question Marks into future Stars, driving substantial growth for Genmab.
Early-stage Bispecific T-cell Engagers (e.g., DuoBody-CD3xCD20, DuoBody-CD3xCD30)
Genmab’s early-stage bispecific T-cell engagers, such as DuoBody-CD3xCD20 and DuoBody-CD3xCD30, represent a significant portion of its proprietary pipeline. These innovative therapies are typically in early clinical development, often Phase 1 or 2 trials, indicating their nascent stage.
These programs exhibit high growth potential owing to their novel mechanisms of action and wide-ranging applications within oncology. However, they currently hold minimal to no market share, reflecting their early-stage status. For context, the global bispecific antibody market was valued at approximately USD 2.1 billion in 2023 and is projected to reach USD 11.5 billion by 2030, showcasing the substantial growth trajectory for such innovative therapies.
The development of these early-stage bispecifics necessitates considerable investment in research and clinical trials. Their progression to becoming market-leading products, or 'Stars' in the BCG matrix, is contingent upon achieving successful clinical outcomes and regulatory approvals. This makes them classic examples of 'Question Marks' within Genmab's portfolio, requiring strategic decisions regarding resource allocation and development focus.
Next-generation Immune Checkpoint Modulators
Genmab's next-generation immune checkpoint modulators, such as acasunlimab and other early-stage targets, are positioned as potential Stars in its BCG matrix. These innovative therapies are entering a dynamic immunotherapy market, signaling high growth potential. However, their current market share is minimal, reflecting their early stage of clinical development.
Significant investment in research and development is crucial for these candidates. Genmab must prove their efficacy and safety to gain traction and establish market share. Success in these early phases will determine if they can transition from question marks to established Stars in Genmab's portfolio.
- Early-stage development: Acasunlimab and other undisclosed targets are in early clinical phases, representing significant R&D investment.
- High-growth potential: These next-generation modulators target the rapidly evolving immunotherapy landscape, offering substantial future growth prospects.
- Negligible current market share: Despite their innovative nature, these candidates currently hold a minimal share of the market due to their developmental stage.
- Path to Star status: Demonstrating efficacy and safety through ongoing trials is key to capturing market share and achieving Star status.
Undisclosed Preclinical Programs and Novel Antibody Technologies
Genmab’s undisclosed preclinical programs represent its Stars, characterized by significant, untapped potential. These early-stage initiatives, focusing on novel antibody technologies beyond current platforms, hold the promise of future market leadership, much like Genmab’s successful therapies have in the past.
These programs, while not yet contributing to revenue, demand substantial research and development investment. For instance, the company consistently allocates a significant portion of its R&D budget to exploring new therapeutic modalities, a strategy that fuels its pipeline but also carries inherent risks associated with early-stage drug discovery.
- High Growth Potential: These preclinical assets aim to address unmet medical needs, potentially creating entirely new markets.
- Zero Market Share: As they are in the earliest stages, they have no current commercial presence.
- Substantial Investment Required: Progressing these programs through costly clinical trials necessitates significant capital outlay.
- High Risk: The inherent uncertainty of preclinical and early clinical development means a high probability of failure.
Bispecific Antibodies: From Question Marks to Potential Stars
Genmab's early-stage bispecific T-cell engagers, such as DuoBody-CD3xCD20 and DuoBody-CD3xCD30, represent a significant portion of its proprietary pipeline and are classic examples of Question Marks. These therapies are in early clinical development, often Phase 1 or 2 trials, indicating their nascent stage with high growth potential in the rapidly expanding bispecific antibody market, which was valued at approximately USD 2.1 billion in 2023 and projected to reach USD 11.5 billion by 2030. However, they currently hold minimal to no market share, requiring substantial investment in R&D to potentially transition into Stars.
| Product Candidate | Therapeutic Area | BCG Category | Key Considerations |
|---|---|---|---|
| GEN3014 (HexaBody-CD38) | Multiple Myeloma | Question Mark | Potential blockbuster, dependent on J&J option (Q1 2025) and demonstrated superiority/complementary role to Darzalex. |
| Rinatabart Sesutecan (Rina-S) | Ovarian Cancer (Star), Endometrial Cancer (Question Mark) | Question Mark (for endometrial cancer) | Phase 3 enrollment for endometrial cancer; success could lead to Star status. |
| DuoBody-CD3xCD20, DuoBody-CD3xCD30 | Oncology | Question Mark | Early clinical development (Phase 1/2), high growth potential in bispecific antibody market, requires significant R&D investment. |
| Acasunlimab & other immune checkpoint modulators | Oncology | Question Mark | Early clinical development, high growth potential in immunotherapy market, needs proven efficacy and safety for market share capture. |
BCG Matrix Data Sources
Our Genmab BCG Matrix is informed by comprehensive market research, including company financial reports, clinical trial data, and industry growth forecasts.
